Abdelhalim Azzi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Abdelhalim Azzi has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
Abdulrahman El Sayed
Laboratory of Lipids and Chronobiology, International Institute of Molecular Mechanisms and Machines (IMol), Polish Academy of Sciences, 00-783, Warsaw, Poland
3 shared publicationsAbdul Rahman El Sayed
The International Institute of Molecular Mechanisms and Machines Polish Academy of Sciences
2 shared publications- Christoph Grunau
IHPE, Univ Perpignan Via Domitia, CNRS, Ifremer, Univ Montpellier
2 shared publications Maciej Zakrzewski
Proteomic Core Facility, IMol Polish Academy of Sciences, Warsaw, Poland
2 shared publicationsPatricia Molina-Ortiz
Laboratory of Functional Genetics, GIGA Research Centre, Université de Liège, Liège, Belgium
2 shared publicationsRemigiusz Serwa
Proteomic Core Facility, IMol Polish Academy of Sciences, Warsaw, Poland
2 shared publications
Latest Publications
- Open Access
SHIP2-SRC-β-catenin signaling axis sustains thymidylate synthase expression and promotes fluoropyrimidine resistance.
Fluoropyrimidine-based chemotherapies, including 5-fluorouracil (5-FU) and floxuridine (FuDR), are widely used in cancer treatment, but their efficacy is limited by adaptive resistance driven by TYMS upregulation. The upstream mechanisms controlling TYMS expression remain poorly defined. Here, we identify INPPL1 (SHIP2) as a critical regulator of TYMS expression and fluoropyrimidine response in breast cancer cells. We show that SHIP2 enhances basal and drug-induced TYMS expression at the transcriptional level independently of its phosphatase activity. Mechanistically, SHIP2 increases SRC levels and nuclear accumulation of β-catenin, driving TYMS expression. Inhibition of SRC or β-catenin suppresses TYMS induction and restores sensitivity to FuDR. Importantly, SHIP2 rewires TYMS regulation from a P53-dependent program to a β-catenin-driven pathway, enabling sustained TYMS expression under chemotherapeutic stress. Consistent with this model, differential sensitivity to SHIP2 depletion correlates with baseline TYMS levels across cell lines. Analysis of patient cancer datasets reveals that high INPPL1 expression correlates with increased TYMS levels and poor clinical outcomes. These findings identify SHIP2 as a non-canonical regulator of TYMS and a potential therapeutic target to overcome fluoropyrimidine resistance.
Open AccessSHIP2-SRC-β-catenin signaling axis sustains thymidylate synthase expression and promotes fluoropyrimidine resistance.
Fluoropyrimidine-based chemotherapies, including 5-fluorouracil (5-FU) and floxuridine (FuDR), are widely used in cancer treatment, but their efficacy is limited by adaptive resistance driven by TYMS upregulation. The upstream mechanisms controlling TYMS expression remain poorly defined. Here, we identify INPPL1 (SHIP2) as a critical regulator of TYMS expression and fluoropyrimidine response in breast cancer cells. We show that SHIP2 enhances basal and drug-induced TYMS expression at the transcriptional level independently of its phosphatase activity. Mechanistically, SHIP2 increases SRC levels and nuclear accumulation of β-catenin, driving TYMS expression. Inhibition of SRC or β-catenin suppresses TYMS induction and restores sensitivity to FuDR. Importantly, SHIP2 rewires TYMS regulation from a P53-dependent program to a β-catenin-driven pathway, enabling sustained TYMS expression under chemotherapeutic stress. Consistent with this model, differential sensitivity to SHIP2 depletion correlates with baseline TYMS levels across cell lines. Analysis of patient cancer datasets reveals that high INPPL1 expression correlates with increased TYMS levels and poor clinical outcomes. These findings identify SHIP2 as a non-canonical regulator of TYMS and a potential therapeutic target to overcome fluoropyrimidine resistance.
- Open Access
SHIP2 oligomeric states and activity regulate cellular responses to sodium arsenate-induced stress granule dynamics
Protein dimerization plays a central role in regulating enzymatic activity, signal transduction, and transcription factor function. Within the PI3K family, different modes of oligomerization have been reported. However, the oligomerization of lipid 5-phosphatases and its functional consequences have not been described. Here, we show for the first time that the lipid 5-phosphatase SHIP2 exists as a homodimer in cells, with its N-terminal region serving as the primary dimerization domain. We further demonstrate that SHIP2 dimerization has no major impact on its catalytic activity but instead profoundly affects its interactome. Interestingly, we identify the stress granule marker G3BP1 as one of the SHIP2 interactors whose association is moderately influenced by SHIP2 oligomerization states. Furthermore, we show that changes in SHIP2 protein levels, enzymatic activity, and oligomeric state alter the cellular response to sodium arsenate-induced stress. In addition, variation in SHIP2 levels and activity affects stress granule size and dynamics. Together, these findings identify SHIP2 oligomerization as a previously unrecognized regulatory mechanism linking phosphoinositide signaling to stress granule biology.
Open AccessSHIP2 oligomeric states and activity regulate cellular responses to sodium arsenate-induced stress granule dynamics
Protein dimerization plays a central role in regulating enzymatic activity, signal transduction, and transcription factor function. Within the PI3K family, different modes of oligomerization have been reported. However, the oligomerization of lipid 5-phosphatases and its functional consequences have not been described. Here, we show for the first time that the lipid 5-phosphatase SHIP2 exists as a homodimer in cells, with its N-terminal region serving as the primary dimerization domain. We further demonstrate that SHIP2 dimerization has no major impact on its catalytic activity but instead profoundly affects its interactome. Interestingly, we identify the stress granule marker G3BP1 as one of the SHIP2 interactors whose association is moderately influenced by SHIP2 oligomerization states. Furthermore, we show that changes in SHIP2 protein levels, enzymatic activity, and oligomeric state alter the cellular response to sodium arsenate-induced stress. In addition, variation in SHIP2 levels and activity affects stress granule size and dynamics. Together, these findings identify SHIP2 oligomerization as a previously unrecognized regulatory mechanism linking phosphoinositide signaling to stress granule biology.
- Open Access
- 1 May 2026
- Published by KEAI Publishing in Genes & Diseases
- Vol. 13 (3) , 101905
PI3Kα-RAS interface disruption as a new therapeutic strategy
- 1 May 2026
- Published by KEAI Publishing in Genes & Diseases
- Vol. 13 (3) , 101905
Open AccessPI3Kα-RAS interface disruption as a new therapeutic strategy
- Open Access
- 19 April 2026
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1024, 178872
Lysosomal accumulation of masitinib alters autophagy via pH-dependent trapping
- 19 April 2026
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1024, 178872
Open AccessLysosomal accumulation of masitinib alters autophagy via pH-dependent trapping
- Open Access
- 28 January 2026
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 24 (1)
The mTORC2 component SIN1 post-transcriptionally regulates TYMS levels and modulates P53 activity in response to 5-FU chemotherapy
Transcriptional and translation control of thymidylate synthase (TYMS) is poorly understood, particularly in response to chemotherapeutic drugs such as 5-F
- 28 January 2026
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 24 (1)
Open AccessThe mTORC2 component SIN1 post-transcriptionally regulates TYMS levels and modulates P53 activity in response to 5-FU chemotherapy
Transcriptional and translation control of thymidylate synthase (TYMS) is poorly understood, particularly in response to chemotherapeutic drugs such as 5-F
- Open Access
Mechanistic Insights into TYSM Protein Regulation by mTORC2 in Response to Chemotherapy
Transcriptional and translation control of thymidylate synthase (TYMS) is poorly understood, particularly in response to chemotherapeutic drugs such as 5-Fluorouracil (5-FU) and its derivatives. The current study addressed this gap by demonstrating a biphasic response in TYMS protein levels upon 5-FU treatment. Indeed, we observe an initial reduction within the first few hours, followed by a marked increase at 24 hours. These changes occurred independently of transcriptional regulation, as TYMS mRNA levels remained stable during the early phase and showed only a moderate increase later. We further showed that neither autophagy nor proteasomal degradation contributed to this dynamic, but instead it is driven by change in its translation. Using thermal proteome profiling, we identified SIN1, a key component of the mTORC2 complex, as a key regulator of TYMS protein levels. Functional studies revealed that SIN1 depletion negatively alters TYMS levels and dynamics and sensitizes cancer cells to 5-FU-mediated cell death. These findings uncover a novel mechanism controlling TYMS protein levels and suggest that targeting SIN1 may represent a promising strategy to enhance the therapeutic efficacy of 5-FU-based treatments.
Open AccessMechanistic Insights into TYSM Protein Regulation by mTORC2 in Response to Chemotherapy
Transcriptional and translation control of thymidylate synthase (TYMS) is poorly understood, particularly in response to chemotherapeutic drugs such as 5-Fluorouracil (5-FU) and its derivatives. The current study addressed this gap by demonstrating a biphasic response in TYMS protein levels upon 5-FU treatment. Indeed, we observe an initial reduction within the first few hours, followed by a marked increase at 24 hours. These changes occurred independently of transcriptional regulation, as TYMS mRNA levels remained stable during the early phase and showed only a moderate increase later. We further showed that neither autophagy nor proteasomal degradation contributed to this dynamic, but instead it is driven by change in its translation. Using thermal proteome profiling, we identified SIN1, a key component of the mTORC2 complex, as a key regulator of TYMS protein levels. Functional studies revealed that SIN1 depletion negatively alters TYMS levels and dynamics and sensitizes cancer cells to 5-FU-mediated cell death. These findings uncover a novel mechanism controlling TYMS protein levels and suggest that targeting SIN1 may represent a promising strategy to enhance the therapeutic efficacy of 5-FU-based treatments.
- 6 April 2023
- Published by American Society of Hematology in Blood
- Vol. 141 (14) , 1708-1717
INPP5K controls the dynamic structure and signaling of wild-type and mutated, leukemia-associated IL-7 receptors
The downstream signaling of the interleukin-7 (IL-7) receptor (IL-7R) plays important physiological and pathological roles, including the differentiation of lymphoid cells and proliferation of acute lymphoblastic leukemia cells. Gain-of-function mutations in the IL-7Rα chain, the specific component of the receptor for IL-7, result in constitutive, IL-7–independent signaling and trigger acute lymphoblastic leukemia. Here, we show that the loss of the phosphoinositide 5-phosphatase INPP5K is associated with increased levels of the INPP5K substrate phosphatidylinositol 4,5-bisphosphate (PtdIns[4,5]P2) and causes an altered dynamic structure of the IL-7 receptor. We discovered that the IL-7Rα chain contains a very conserved positively charged polybasic amino acid sequence in its cytoplasmic juxtamembrane region; this region establish stronger ionic interactions with negatively charged PtdIns(4,5)P2 in the absence of INPP5K, freezing the IL-7Rα chain structure. This dynamic structural alteration causes defects in IL-7R signaling, culminating in decreased expressions of EBF1 and PAX5 transcription factors, in microdomain formation, cytoskeletal reorganization, and bone marrow B-cell differentiation. Similar alterations after the reduced INPP5K expression also affected mutated, constitutively activated IL-7Rα chains that trigger leukemia development, leading to reduced cell proliferation. Altogether, our results indicate that the lipid 5-phosphatase INPP5K hydrolyzes PtdIns(4,5)P2, allowing the requisite conformational changes of the IL-7Rα chain for optimal signaling.
- 6 April 2023
- Published by American Society of Hematology in Blood
- Vol. 141 (14) , 1708-1717
INPP5K controls the dynamic structure and signaling of wild-type and mutated, leukemia-associated IL-7 receptors
The downstream signaling of the interleukin-7 (IL-7) receptor (IL-7R) plays important physiological and pathological roles, including the differentiation of lymphoid cells and proliferation of acute lymphoblastic leukemia cells. Gain-of-function mutations in the IL-7Rα chain, the specific component of the receptor for IL-7, result in constitutive, IL-7–independent signaling and trigger acute lymphoblastic leukemia. Here, we show that the loss of the phosphoinositide 5-phosphatase INPP5K is associated with increased levels of the INPP5K substrate phosphatidylinositol 4,5-bisphosphate (PtdIns[4,5]P2) and causes an altered dynamic structure of the IL-7 receptor. We discovered that the IL-7Rα chain contains a very conserved positively charged polybasic amino acid sequence in its cytoplasmic juxtamembrane region; this region establish stronger ionic interactions with negatively charged PtdIns(4,5)P2 in the absence of INPP5K, freezing the IL-7Rα chain structure. This dynamic structural alteration causes defects in IL-7R signaling, culminating in decreased expressions of EBF1 and PAX5 transcription factors, in microdomain formation, cytoskeletal reorganization, and bone marrow B-cell differentiation. Similar alterations after the reduced INPP5K expression also affected mutated, constitutively activated IL-7Rα chains that trigger leukemia development, leading to reduced cell proliferation. Altogether, our results indicate that the lipid 5-phosphatase INPP5K hydrolyzes PtdIns(4,5)P2, allowing the requisite conformational changes of the IL-7Rα chain for optimal signaling.
- 1 January 2021
- Published by Elsevier in Archives of Biochemistry and Biophysics
- Vol. 697, 108667
Scaffold dependent role of the inositol 5′-phosphatase SHIP2, in regulation of oxidative stress induced apoptosis
- 1 January 2021
- Published by Elsevier in Archives of Biochemistry and Biophysics
- Vol. 697, 108667
Scaffold dependent role of the inositol 5′-phosphatase SHIP2, in regulation of oxidative stress induced apoptosis
- Open Access
- 2 September 2020
- Published by Wiley in FEBS Open Bio
- Vol. 10 (10) , 2191-2205
SHIP2 inhibition alters redox‐induced PI3K/AKT and MAP kinase pathways via PTEN over‐activation in cervical cancer cells
PI(3,4,5)P3 is required for AKT activation. The level of PI(3,4,5)P3 is constantly regulated through balanced synthesis by PI3 kinase and degradation by phosphoinositide phosphatases PTEN and SHIP2, known as negative regulators of AKT. Here, I show that SHIP2 inhibition in cervical cancer cell lines alters H2O2‐mediated AKT and MAPK/ERK pathway activation. In addition, SHIP2 inhibition enhances reactive oxygen species generation. Interestingly, I found that SHIP2 inhibition and H2O2 treatment enhance lipid and protein phosphatase activity of PTEN. Pharmacological targeting or RNAi‐mediated knockdown of PTEN rescue ERK and AKT activation. Using a series of pharmacological and biochemical approaches, I provide evidence that crosstalk between SHIP2 and PTEN occurs upon an increase in oxidative stress to modulate the activity of MAPK and PI3/ATK pathways.
- 2 September 2020
- Published by Wiley in FEBS Open Bio
- Vol. 10 (10) , 2191-2205
Open AccessSHIP2 inhibition alters redox‐induced PI3K/AKT and MAP kinase pathways via PTEN over‐activation in cervical cancer cells
PI(3,4,5)P3 is required for AKT activation. The level of PI(3,4,5)P3 is constantly regulated through balanced synthesis by PI3 kinase and degradation by phosphoinositide phosphatases PTEN and SHIP2, known as negative regulators of AKT. Here, I show that SHIP2 inhibition in cervical cancer cell lines alters H2O2‐mediated AKT and MAPK/ERK pathway activation. In addition, SHIP2 inhibition enhances reactive oxygen species generation. Interestingly, I found that SHIP2 inhibition and H2O2 treatment enhance lipid and protein phosphatase activity of PTEN. Pharmacological targeting or RNAi‐mediated knockdown of PTEN rescue ERK and AKT activation. Using a series of pharmacological and biochemical approaches, I provide evidence that crosstalk between SHIP2 and PTEN occurs upon an increase in oxidative stress to modulate the activity of MAPK and PI3/ATK pathways.